Source - LSE Regulatory
RNS Number : 8075V
Cambridge Cognition Holdings PLC
16 December 2021
 

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Electronic Clinical Outcomes Assessment contract win worth over £500,000

 

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a contract worth over £500,000 to provide electronic clinical outcome assessments ("eCOA") to support a major pharmaceutical client (the "Client") in delivering a Phase II paediatric study over several years. This is the second eCOA contract Cambridge Cognition has secured with the Client in just over a year. The first was of a similar value and referenced in the Company's trading update on 30 June 2020.  

 

To support the Client in establishing the safety and efficacy of a new drug, the Company will collect patients' and parents' experiences with electronic questionnaires, scales and diaries. This data will be collected both in clinics on iPads and at home on smartphones using Cambridge Cognition's eCOA system. Cambridge Cognition's experienced study management team will work closely with the Client to ensure successful use of the software and devices. 

 

The provision of eCOA for clinical trials is a sizeable growth market, valued at over US$1bn per annum and growing at 15% according to market research reports1.  Cambridge Cognition provides eCOA solutions primarily for clinical trials for central nervous systems disorders, such as Alzheimer's disease, although can also support other conditions.

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"At Cambridge Cognition, we pride ourselves on our customer service and I am pleased to see this recognised with repeat custom from a major pharmaceutical client.  In addition, it is a success for our commercialisation strategy as it again shows that our eCOA solution can be a standalone product, as well as an upsell with cognitive assessments for clinical trials."

 

1. Grand View Research, Electronic Clinical Outcome Assessment Solutions Market, 2018

 

For further information, contact:

 

Cambridge Cognition Holdings PLC

Matthew Stork, Chief Executive Officer

Sally Jennings, Head of Marketing and Communications

Tel: 012 2381 0700

press@camcog.com

finnCap Ltd (NOMAD and Joint Broker)

Geoff Nash / Simon Hicks

Alice Lane / Charlotte Sutcliffe

Tel: 020 7220 0500

(Corporate Finance)

(Corporate Broking)

Dowgate Capital Limited (Joint Broker)

David Poutney / James Serjeant

Tel: 020 3903 7715

 

IFC Advisory Ltd (Financial PR and IR)

Tim Metcalfe / Graham Herring / Zach Cohen

Tel: 020 3934 6630

 

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTMZMMZRKVGMZM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.